NCT06209099View on ClinicalTrials.gov

Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer

NARecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

January 17, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

November 1, 2025

Conditions
Rectal Cancer
Interventions
PROCEDURE

Nonoperative Management (NOM)

Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Nonoperative Management (NOM)

PROCEDURE

Local Excision (LE)

Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Local Excision (LE)

PROCEDURE

Total Mesorectal Excision (TME)

Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Total Mesorectal Excision (TME)

Trial Locations (1)

100142

RECRUITING

Peking University Cancer Hospital & Institute, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER